NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. (NASDAQ: VTRS). Shareholders who purchased shares of VTRS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/viatris-inc-loss-submission-form-2/?id=147747&from=3 CLASS PERIOD: August 8, 2024 to F ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Viatris To Contact Him Directly To Discuss Their Options If you suffered significant losses in Viatris stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, May 11, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a lead ...

Core Viewpoint - A lawsuit has been filed against Viatris Inc. and certain senior executives for potential violations of federal securities laws, stemming from misleading statements regarding the company's operational status and the impact of a failed FDA inspection on its financial performance [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Western District of Pennsylvania, titled Quinn v. Viatris Inc., et al., No. 25-cv-466, with investors having until June 3, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Viatris securities [2]. Group 2: Company Background and Allegations - Viatris is a global healthcare company that provides medicines to approximately 1 billion patients across over 165 countries [3]. - The complaint claims that Viatris misrepresented its facilities as being in "good operating condition" and suitable for their intended purposes, while downplaying the significance of a Warning Letter issued by the FDA following a failed inspection at its Indore, India facility [3][4]. Group 3: Financial Impact - The failed FDA inspection has had a substantial negative impact on Viatris's financial results, preventing the company from manufacturing and distributing key products, including Lenalidomide [4]. - In its Q4 2024 results released on February 27, 2025, Viatris disclosed that the inspection's repercussions would lower 2025 revenue by approximately $500 million and earnings from operations by about $385 million [5]. - Following this announcement, Viatris's stock price fell roughly 15%, from $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025 [5].

SAN DIEGO, May 09, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Viatris Inc. (NASDAQ: VTRS) securities between August 8, 2024 and February 26, 2025. Viatris is a global healthcare company that supplies medicines to patients across more than 165 countries and territories via its 26 manufacturing and packaging sites worldwide. For more information, submit a form, email attorney Aaron Dumas, Jr., or give u ...

Core Viewpoint - A lawsuit has been filed against Viatris Inc. and certain senior executives for potential violations of federal securities laws, stemming from misleading statements regarding the company's operational conditions and the impact of a failed FDA inspection on its financial performance [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Western District of Pennsylvania, captioned Quinn v. Viatris Inc., et al., No. 25-cv-466, with investors having until June 3, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Viatris securities [2]. Group 2: Company Background and Allegations - Viatris is a global healthcare company supplying medicines to approximately 1 billion patients across over 165 countries [3]. - The complaint claims that Viatris misrepresented its facilities as being in "good operating condition" and committed to high-quality manufacturing standards, despite a Warning Letter from the FDA following a failed inspection at its Indore, India facility [3][4]. Group 3: Financial Impact - The failed FDA inspection significantly impacted Viatris's financial results, preventing the company from manufacturing and distributing key products, including Lenalidomide [4]. - In its Q4 2024 results, Viatris disclosed that the negative impact from the Indore facility's inspection would lower 2025 revenue by approximately $500 million and earnings from operations by about $385 million [5]. - Following this announcement, Viatris's stock price dropped roughly 15%, from $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025 [5].

NEW YORK, May 9, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Viatris investors who were adversely affected by alleged securities fraud between August 8, 2024 and February 26, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2? ...

Core Insights - Viatris Inc. has released positive data from a Phase 3 study on the contraceptive efficacy and safety of XULANE LO, a low-dose weekly dermal patch [1][2] - The company also reported results from a Phase 3 program for a fast-acting formulation of meloxicam, MR-107A-02, for moderate-to-severe acute pain [4][5] Contraceptive Study Findings - XULANE LO demonstrated a Pearl Index (PI) of 4.14, indicating contraceptive efficacy, with a cumulative probability of pregnancy over 13 cycles at 3.7% [2] - The safety profile was favorable, with most treatment-emergent adverse events reported as mild to moderate, and a low rate of unscheduled bleeding and spotting [2][3] - The patch adhesion profile was noted as best-in-class, with only 1.3% of patches completely detaching during the seven-day wear period [3] Pain Management Study Findings - MR-107A-02 showed statistically significant and clinically meaningful results in pain management following herniorrhaphy and bunionectomy surgeries [5][8] - The treatment led to a notable reduction in opioid usage, with 72.6% of patients opioid-free after herniorrhaphy compared to 58.6% in the placebo group, and 56.9% opioid-free after bunionectomy compared to 33.1% in the placebo group [8] Financial Performance - For Q1 2025, Viatris reported total revenues of $3.3 billion, down 11% year-over-year, primarily due to the negative Indore Impact [6][9] - The estimated Indore Impact on total revenues was approximately $140 million, with management projecting a revenue reduction of $500 million for 2025 due to issues at the Indore facility [7][9] - The company reaffirmed its 2025 sales outlook of $13.5 billion to $14 billion, with adjusted EPS guidance raised to $2.16-$2.30 [9][10] Stock Performance - Following the announcements, VTRS stock increased by 10.2%, reaching $9.48 [10]

Core Viewpoint - Viatris Inc. (VTRS) reported better-than-expected first-quarter adjusted earnings of 50 cents per share, surpassing the Zacks Consensus Estimate of 49 cents, although down from 67 cents per share in the same quarter last year [1][15] Financial Performance - Total revenues for the quarter were $3.25 billion, reflecting an 11% year-over-year decline, but still exceeding the Zacks Consensus Estimate of $3.23 billion [1][15] - Adjusted gross margin decreased to 55.9% from 58.8% year-over-year [10] Sales Breakdown - Sales from Developed Markets were $1.9 billion, down 3% on a divestiture-adjusted operational basis, missing the Zacks Consensus Estimate of $1.93 billion [4] - Emerging Markets generated $519.9 million in sales, down 5% on a divestiture-adjusted operational basis, but beating the Zacks Consensus Estimate of $464 million [5] - Sales from Japan, Australia, and New Zealand (JANZ) totaled $276.1 million, down 6% and missing the Zacks Consensus Estimate of $309 million [5] - Greater China sales increased by 4% to $555.5 million, surpassing the Zacks Consensus Estimate of $553 million [5] Product Category Performance - Revenues from Brands decreased by 8% to $2.1 billion, but increased by 3% on a divestiture-adjusted operational basis [6] - Lipitor sales were $388 million, relatively flat year-over-year, while Norvasc and Lyrica sales declined [6] - Generics revenue was $1.1 billion, down 16%, with an operational decline of 11% [7][9] Future Guidance - Viatris maintains its total revenue guidance for 2025 at $13.5-$14 billion and adjusted earnings per share guidance at $2.16-$2.30, updated from a previous range of $2.12-$2.26 [12] Research and Development Updates - Positive results were reported from phase III studies for Effexor and a novel formulation of meloxicam, with plans to submit a new drug application to the FDA by the end of 2025 [13][14]

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth?Viatris Inc. ( VTRS ) has announced its Q1 2025 earnings earlier today and the market's response is initially positive - it's stock is up nearly 10% at the time of writing. Let's consider some headline figures.The g ...

Viatris (VTRS) reported $3.25 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 11.2%. EPS of $0.50 for the same period compares to $0.67 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $3.23 billion, representing a surprise of +0.81%. The company delivered an EPS surprise of +2.04%, with the consensus EPS estimate being $0.49.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how the ...